Protocol Ledger

NCT06907173 · Phase III · RECRUITING

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

Interventional Phase III clinical trial protocol NCT06907173 sponsored by University of Virginia in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-06 Enrollment: 770 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06907173
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)770 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06907173
Protocol FieldVerified Registry Value
NCT IdentifierNCT06907173
Consolidated Lead SponsorUniversity of Virginia
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment770 participants (ESTIMATED)
Registered Start Date2026-03-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI